We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+18.89%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
+$357M
Cap. Flow
+$201M
Cap. Flow %
8.05%
Top 10 Hldgs %
59.89%
Holding
57
New
8
Increased
13
Reduced
5
Closed
4

Top Buys

1
MBX
MBX Biosciences
MBX
+$137M
2
ASND icon
Ascendis Pharma A/S
ASND
+$18M
3
ORKA
Oruka Therapeutics
ORKA
+$16.6M
4
ALKS icon
Alkermes
ALKS
+$15.4M
5
LXEO icon
Lexeo Therapeutics
LXEO
+$14.9M

Top Sells

1
EWTX icon
Edgewise Therapeutics
EWTX
+$17.9M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$16.1M
3
PCVX icon
Vaxcyte
PCVX
+$14.4M
4
APLT
Applied Therapeutics
APLT
+$10.7M
5
PEPG icon
PepGen
PEPG
+$9.47M

Sector Composition

1 Healthcare 99.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
51
Nuvation Bio
NUVB
$2.02B
$2.79M 0.11%
+1,218,236
New +$3.72M
ACRS icon
52
Aclaris Therapeutics
ACRS
$793M
$304K 0.01%
264,377
– –
PVLA
53
Palvella Therapeutics
PVLA
$2.26B
$267K 0.01%
+15,942
New +$233K
ANTX icon
54
AN2 Therapeutics
ANTX
$169M
– –
-2,088,889
Closed -$4.49M
APLT
55
DELISTED
Applied Therapeutics
APLT
– –
-2,286,135
Closed -$10.7M
MGX icon
56
Metagenomi Therapeutics
MGX
$46.7M
– –
-245,692
Closed -$1M
CERE
57
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-393,000
Closed -$16.1M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2024 Portfolio in Review

As of Q3 2024, Frazier Life Sciences Management held 57 positions worth $2.5B, up 17% from $2.14B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Frazier Life Sciences Management deployed $201M of net new capital in Q3 2024, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was MBX Biosciences: 5,985,347 shares worth $155M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Edgewise Therapeutics, an estimated $17.9M trimmed.

  • Frazier Life Sciences Management's largest Q3 2024 buy was MBX Biosciences: 5,985,347 shares worth $155M.
  • Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q3 2024, an estimated $10.9M increase.
  • Frazier Life Sciences Management's biggest Q3 2024 reduction was Edgewise Therapeutics, cutting an estimated $17.9M.
  • Frazier Life Sciences Management fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $16.1M.
  • Frazier Life Sciences Management's ten largest holdings make up 60% of its $2.5B portfolio in Q3 2024.
  • Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2024.
  • Frazier Life Sciences Management's portfolio value rose 17% quarter-over-quarter to $2.5B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.